Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains
James Brett Case,Samantha Mackin,John M. Errico,Zhenlu Chong,Emily A Madden,Bradley M. Whitener,Barbara Guarino,Michael Schmid,Kim Rosenthal,Kuishu Ren,Ha V. Dang,Gyorgy Snell,Ana Jung,Lindsay Droit,Scott A. Handley,Peter Halfmann,Yoshihiro Kawaoka,James E. Crowe,Daved H. Fremont,Herbert W. Virgin,Yueh Ming Loo,Mark T. Esser,Lisa A. Purcell,Davide Corti,Michael S. Diamond +24 more
TLDR
In this paper , the authors report on the protection of two monoclonal antibody therapies (S309 and AZD7442) against SARS-CoV-2 Omicron lineage strains (BA.1, BA.2, and BA.1.1).Abstract:
Abstract Omicron variant strains encode large numbers of changes in the spike protein compared to historical SARS-CoV-2 isolates. Although in vitro studies have suggested that several monoclonal antibody therapies lose neutralizing activity against Omicron variants, the effects in vivo remain largely unknown. Here, we report on the protective efficacy against three SARS-CoV-2 Omicron lineage strains (BA.1, BA.1.1, and BA.2) of two monoclonal antibody therapeutics (S309 [Vir Biotechnology] monotherapy and AZD7442 [AstraZeneca] combination), which correspond to ones used to treat or prevent SARS-CoV-2 infections in humans. Despite losses in neutralization potency in cell culture, S309 or AZD7442 treatments reduced BA.1, BA.1.1, and BA.2 lung infection in susceptible mice that express human ACE2 (K18-hACE2) in prophylactic and therapeutic settings. Correlation analyses between in vitro neutralizing activity and reductions in viral burden in K18-hACE2 or human FcγR transgenic mice suggest that S309 and AZD7442 have different mechanisms of protection against Omicron variants, with S309 utilizing Fc effector function interactions and AZD7442 acting principally by direct neutralization. Our data in mice demonstrate the resilience of S309 and AZD7442 mAbs against emerging SARS-CoV-2 variant strains and provide insight into the relationship between loss of antibody neutralization potency and retained protection in vivo. read more
Citations
More filters
Posted ContentDOI
The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2
Andrea L. Cathcart,Colin Havenar-Daughton,Florian A. Lempp,Daphne Ma,Michael C. Schmid,Maria L. Agostini,Barbara Guarino,Julia di Iulio,Laura E. Rosen,Heather Tucker,Joshua Dillen,Sambhavi Subramanian,Barbara Sloan,Siro Bianchi,Jason A. Wojcechowskyj,Jiayi Zhou,Hannah Kaiser,Arthur Chase,Elvin J. Lauron,Martin Montiel-Ruiz,Roberto Spreafico,Julia Noack,Nadine Czudnochowski,Anna Sahakyan,Dora Pinto,Christian Saliba,Exequiel Delotta,Arnold Park,Elisabetta Cameroni,Sarah Ledoux,Adam Werts,Christophe Colas,Leah Soriaga,Amalio Telenti,Lisa A. Purcell,Seungmin Hwang,Gyorgy Snell,Herbert W. Virgin,Davide Corti,Christy M. Hebner +39 more
TL;DR: In this article, dual action monoclonal antibodies (mAbs) targeting the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were derived from a parent antibody (S309) isolated from memory B cells of a 2003 SARS CoV survivor.
Journal ArticleDOI
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2
Ryuta Uraki,Maki Kiso,Shun Iida,Masaki Imai,Emi Takashita,Makoto Kuroda,Peter Halfmann,Samantha Loeber,Tadashi Maemura,Seiya Yamayoshi,Seiichiro Fujisaki,Zhongde Wang,Mutsumi Ito,Michiko Ujie,Kiyoko Iwatsuki-Horimoto,Yuri Furusawa,R. Wright,Zhenlu Chong,Seiya Ozono,Atsuhiro Yasuhara,Hiroshi Ueki,Yuko Sakai-Tagawa,Rongxiu Li,Yanan Liu,Deanna Larson,Michiko Koga,Takeya Tsutsumi,Eisuke Adachi,Makoto Saito,Shinya Yamamoto,Masao Hagihara,Keiko Mitamura,Tetsuro Sato,Masayuki Hojo,Shin-ichiro Hattori,Kenji Maeda,Riccardo Valdez,Pamela E. Bennett-Baker,Zijin Chu,Dawson Davis,Theresa Kowalski-Dobson,Ashley Eckard,Carmen Gherasim,Wolf Gremel,Kathy Lindsey,David M Manthei,A. Meyers,Julio Zuniga Moya,Aaron Rico,Emily Stoneman,Victoria Le Blanc,Savanna Sneeringer,Lauren Warsinske,Moe Okuda,Jurika Murakami,C. Duong,Sucheta Godbole,Daniel C. Douek,Ken Maeda,Shinji Watanabe,Aubree Gordon,Norio Ohmagari,Hiroshi Yotsuyanagi,Michael S. Diamond,Hideki Hasegawa,Hiroaki Mitsuya,Tadaki Suzuki,Yoshihiro Kawaoka +67 more
TL;DR: In this article , the authors evaluated the replicative ability and pathogenicity of authentic infectious BA.2 isolates in immunocompetent and human ACE2-expressing mice and hamsters.
Journal ArticleDOI
Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
TL;DR: The omicron variant (B.1.529) was identified at the end of November, 2021, and rapidly spread worldwide as mentioned in this paper , and the BA.2 subvariant is the most dominant variant in the world.
letters-and-commentsDOI
Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
Journal ArticleDOI
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
Young-Jun Park,Dora Pinto,Alexandra C. Walls,Zhuoming Li,Anna De Marco,Fabio Benigni,Fabrizia Zatta,Chiara Silacci-Fregni,Jessica Bassi,Kaitlin R. Sprouse,Amin Addetia,John E. Bowen,Cameron Stewart,Martina Giurdanella,Christian Saliba,Barbara Guarino,Michael Schmid,Nicholas Franko,Jennifer Logue,Ha V. Dang,Kevin Hauser,J. Di Iulio,William A. Rivera,Gretja Schnell,Anushka Rajesh,Jiayi Zhou,Nisar A. Farhat,Hannah Kaiser,Martin Montiel-Ruiz,Julia Noack,Florian A. Lempp,Javier Janer,Rana Abdelnabi,Piet Maes,Paolo Ferrari,Alessandro Ceschi,Olivier Giannini,G. D. de Melo,Lauriane Kergoat,Hervé Bourhy,Johan Neyts,Leah Soriaga,Lisa A. Purcell,Gyorgy Snell,Sean P. J. Whelan,Antonio Lanzavecchia,Herbert W. Virgin,Luca Piccoli,Helen Y. Chu,Matteo Samuele Pizzuto,Davide Corti,David Veesler +51 more
TL;DR: It is shown that hybrid immunity or vaccine boosters result in potent plasma neutralizing activity against Omicron BA.1 and BA.2 and that breakthrough infections, but not vaccination-only, induceneutralizing activity in the nasal mucosa.
References
More filters
Journal ArticleDOI
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.
Jun Lan,Jiwan Ge,Jinfang Yu,Sisi Shan,Huan Zhou,Shilong Fan,Qi Zhang,Xuanling Shi,Qisheng Wang,Linqi Zhang,Xinquan Wang +10 more
TL;DR: High-resolution crystal structures of the receptor-binding domain of the spike protein of SARS-CoV-2 and SARS -CoV in complex with ACE2 provide insights into the binding mode of these coronaviruses and highlight essential ACE2-interacting residues.
Journal ArticleDOI
UCSF ChimeraX: Meeting modern challenges in visualization and analysis.
Thomas D. Goddard,Conrad C. Huang,Elaine C. Meng,Eric F. Pettersen,Gregory S. Couch,John H. Morris,Thomas E. Ferrin +6 more
TL;DR: This article highlights some specific advances in the areas of visualization and usability, performance, and extensibility in ChimeraX.
Journal ArticleDOI
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.
Xiuyuan Ou,Yan Liu,Xiaobo Lei,Pei Li,Dan Mi,Lili Ren,Li Guo,Ruixuan Guo,Ting Chen,Jiaxin Hu,Zichun Xiang,Zhixia Mu,Xing Chen,Jieyong Chen,Keping Hu,Qi Jin,Jianwei Wang,Zhaohui Qian +17 more
TL;DR: It is shown that the SARS-CoV-2 spike protein is less stable than that of SARS -CoV, and limited cross-neutralization activities between SARS and COVID-19 patients’ sera showlimited cross- neutralization activities, suggesting that recovery from one infection might not protect against the other.
Journal ArticleDOI
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Dora Pinto,Young-Jun Park,Martina Beltramello,Alexandra C. Walls,M. Alejandra Tortorici,M. Alejandra Tortorici,Siro Bianchi,Stefano Jaconi,Katja Culap,Fabrizia Zatta,Anna De Marco,Alessia Peter,Barbara Guarino,Roberto Spreafico,Elisabetta Cameroni,James Brett Case,Rita E. Chen,Colin Havenar-Daughton,Gyorgy Snell,Amalio Telenti,Herbert W. Virgin,Antonio Lanzavecchia,Michael S. Diamond,Katja Fink,David Veesler,Davide Corti +25 more
TL;DR: Several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which was identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS- coV) in 2003, and one antibody (named S309) potently neutralization, which may limit the emergence of neutralization-escape mutants.
Journal ArticleDOI
Potently neutralizing and protective human antibodies against SARS-CoV-2.
Seth J. Zost,Pavlo Gilchuk,James Brett Case,Elad Binshtein,Rita E. Chen,Joseph P. Nkolola,Alexandra Schäfer,Joseph X. Reidy,Andrew Trivette,Rachel S. Nargi,Rachel E. Sutton,Naveenchandra Suryadevara,David R. Martinez,Lauren E. Williamson,Elaine C. Chen,Taylor Jones,Samuel Day,Luke Myers,Ahmed O. Hassan,Natasha M. Kafai,Emma S. Winkler,Julie M. Fox,Swathi Shrihari,Benjamin K. Mueller,Jens Meiler,Jens Meiler,Abishek Chandrashekar,Noe B. Mercado,James J. Steinhardt,Kuishu Ren,Yueh-Ming Loo,Nicole L. Kallewaard,Broc T. McCune,Shamus P. Keeler,Michael J. Holtzman,Dan H. Barouch,Lisa E. Gralinski,Ralph S. Baric,Larissa B. Thackray,Michael S. Diamond,Robert H. Carnahan,James E. Crowe +41 more
TL;DR: An analysis identifies human monoclonal antibodies that potently neutralize wild-type SARS-CoV-2 and protect animals from disease, including two that synergize in a cocktail, suggesting that these could be candidates for use as therapeutic agents for the treatment of COVID-19 in humans.
Related Papers (5)
Viral epitopes and monoclonal antibodies: isolation of blocking antibodies that inhibit virus neutralization.
The appearance of complement-requiring neutralizing antibodies by immunization and infection with herpes simplex virus.
A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in rhesus macaques
Ronald R. Cobb,Joseph P. Nkolola,Pavlo Gilchuk,Abishek Chandrashekar,Robert V. House,Christopher G. Earnhart,Nicole M. Dorsey,Svetlana A. Hopkins,Doris M Snow,Rita E. Chen,Laura A. VanBlargan,Manuel Hechenblaickner,Brian Hoppe,Laura Collins,Milan T. Tomic,Genevieve H. Nonet,Kyal Hackett,James C. Slaughter,Michael S. Diamond,Robert H. Carnahan,Dan H. Barouch,James E. Crowe +21 more